RxDoctor Payments Data

Devanshi Mehta, MD

Pulmonary Disease · Tyler, TXNPI 1831576784

Payments from drug & device makers

$843in general payments, 2019–2025

Across 49 payments — averaging $17.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$225
  • Insmed, Inc.$217
  • Sanofi$84
  • Merck$67
  • Boehringer Ingelheim$59
  • AstraZeneca$36
  • plus $154 from 7 others

What the payments were for

  • Food & beverage$843100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$843 in reported general payments places this provider in the 30th percentile of 904 pulmonary disease providers in Texas.

See all pulmonary disease providers in Texas

Medicare billing

Part B allowed, 2024
$21,991
Medicare patients
97
Services billed
139

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other pulmonary disease in Tyler

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →